United Kingdom - English - myHealthbox

actavis group ptc ehf - linezolid - film-coated tablets - 600mg - other antibacterials - nosocomial pneumonia community acquired pneumonia linezolid is indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration. (see section 5.1 for the appropriate organisms). linezolid is not active against infections caused by gram negative pathogens. specific therapy against gram negative organisms must be initiated concomitantly if a gram negative pathogen is documented or suspected.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - linezolid - film-coated tablet - linezolid 600 mg - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - linezolid - film coated tablet - 600 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - citalopram hydrobromide, quantity: 49.98 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; hypromellose; maize starch; lactose monohydrate; purified talc; microcrystalline cellulose; glycerol; macrogol 6000; magnesium stearate; titanium dioxide; copovidone - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - citalopram hydrobromide, quantity: 24.99 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; glycerol; hypromellose; titanium dioxide; lactose monohydrate; sodium starch glycollate; magnesium stearate; copovidone; purified talc; macrogol 6000 - treatment of major depression.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 25.548 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; mannitol; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - escitalopram oxalate, quantity: 12.774 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; mannitol; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - escitalopram oxalate, quantity: 25.548 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; maize starch; magnesium stearate; mannitol; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - escitalopram oxalate, quantity: 12.774 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; mannitol; titanium dioxide; hypromellose; macrogol 6000 - treatment of major depression. ,treatment of social anxiety disorder (social phobia). ,treatment of generalised anxiety disorder. ,treatment of obsessive-compulsive disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - dapoxetine hydrochloride, quantity: 33.6 mg (equivalent: dapoxetine, qty 30 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; titanium dioxide; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; iron oxide yellow; microcrystalline cellulose; hypromellose; triacetin; iron oxide black - priligy is indicated for the treatment of premature ejaculation (pe) in men 18 to 64 years of age, who have all of the following: an intravaginal ejaculatory latency time (ielt) of less than two minutes; and persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes; and marked personal distress or interpersonal difficulty as a consequence of pe; and poor control over ejaculation.